SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease
£3.7 million seed financing supported by consortium of new and existing investors will fund continued preclinical development of therapeutic pipeline programmes.
Exeter, UK — 18 March 2024: SENISCA, an award-winning biotechnology company developing RNA-based senotherapeutics to treat age-related disease, today announces it has raised an additional £3.7 million in funding. This comprises significant backing from SENISCA’s strong investor base, including Emerging Longevity Ventures, QantX, the R42 Group, Trend Investment Group and Apex Ventures, and investment from new funds including Lifespan Vision Ventures. In addition to the total investor capital raised of £7.1 million to date, SENISCA, through prestigious Innovate UK grants, awards, and commercial relationships, has also gained an additional £1.1 million in non-dilutive funding and commercial revenue, further validating the potential of the Company’s proprietary scientific approach.
SENISCA, a spinout from the University of Exeter, has developed proprietary technology that harnesses RNA biology to reprogram aged ‘senescent’ cells. Senescent cells behave differently to young, healthy cells in several ways, such as ceasing growth and secreting pro-inflammatory chemicals. Senescent cells, with a pro-inflammatory profile and disrupted function, are emerging as causal factors for multiple age-related diseases.
SENISCA has identified a novel and druggable component of the cellular senescence response, RNA splicing dysregulation, which can be specifically targeted in the context of multiple pharmacological and skin health indications.
The proceeds of SENISCA’s largest fundraise to date will support continued rapid company evolution and the preclinical development of the Company’s senotherapeutic programmes, that target the causes of age-related disease via RNA splicing regulation, resulting in cellular reprogramming and disease modification by attenuating senescence.
Dr Sarah Cole, CEO of SENISCA, commented: “This financing round represents another significant milestone for SENISCA. We’ve raised nearly double the previous rounds, enabling us to accelerate the development of our highly promising pipeline through preclinical stages and towards benefiting patients in the clinic. We thank our investors for their continued support and look forward to rapidly advancing towards our goal of becoming a world-leader in the development and use of senotherapeutics that target cellular ageing to treat complex disease.”